Sophiris Bio Inc SPHS

Healthcare Biotechnology

Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.

EXPM:SPHS - Post by User

Sophiris Bio Inc

Bullboard Posts

Post by sandufon Sep 22, 2014 2:29pm

172 Views

Post# 22959100

Price Levels

I really think that the price of this stock is being manipulated. Just look at the current volumes and prices. Small trades driving the price up followed by deep lows where the major trades are being made. I can't afford to get out right now as I have to wait for $13.50/shr (C) to the break even point! Sanduf

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload